A Research Study Comparing RYBELSUS® to Other Blood Sugar Lowering Tablets in People Living in America With Type 2 Diabetes (REALYSE)

PHASE4CompletedINTERVENTIONAL
Enrollment

1,020

Participants

Timeline

Start Date

September 1, 2021

Primary Completion Date

June 18, 2025

Study Completion Date

June 18, 2025

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

semaglutide

Oral administration The doctor will give a prescription for the medicine and tell how to take it.

DRUG

oral glucose-lowering medications (commercially available)

Oral administration The doctor will give a prescription for the medicine and tell how to take it.

Trial Locations (22)

15236

Preferred Primary Care Physicians_Pittsburgh, Pittsburgh

19114

Tristar Clin Investigations, PC, Philadelphia

27215

Kernodle Clin Dpt-Pvt Diagnost, Burlington

27529

WakeMed Garner Hlthplx, Garner

28277

OnSite Clinical Solutions, LLC_Charlotte, Charlotte

29621

AnMed Health IMA, Anderson

30060

DC Research Works, Marietta

30067

Urban Family Practice Assoc, Marietta

33175

Reyes Clinical Research, Inc, Miami

43213

Central Ohio Clinical Research LLC, Columbus

44718

Diab & Endo Assoc of Stark Co, Canton

58104

Valley Weight Loss Clinic, Fargo

60077

Endeavor Health, Skokie

61603

UnityPoint Health-Diabetes Care Center, Peoria

62033

Macoupin Research Group, Gillespie

75246

Baylor Scott & White Res Inst, Dallas

78130

Hill Country Medical Associates, New Braunfels

78258

DCT-Stone Oak, San Antonio

84790

Chrysalis Clinical Research, St. George

92037

Scripps Whittier Diabetes Inst, La Jolla

92627

FDRC, Costa Mesa

19107-6810

Jefferson Endocrinology Assocs, Philadelphia

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY